Side effects of minocycline treatment in patients with fragile X syndrome and exploration of outcome measures.
Minocycline can rescue the dendritic spine and synaptic structural abnormalities in the fragile X knock-out mouse. This is a review and preliminary survey to document side effects and potential outcome measures for minocycline use in the treatment of individuals with fragile X syndrome. We surveyed 50 patients with fragile X syndrome who received minocycline for at least 2 weeks and found that the most common reported side effect is gastrointestinal difficulty, including loss of appetite. The families reported an improvement in language and behavioral areas. Outcome measures in the design of future randomized clinical trials should include both behavioral and language measures. As with any other treatments, we emphasize that randomized clinical trials are needed to determine the efficacy of minocycline in fragile X syndrome.
Utari
Agustini
A
M.I.N.D. Institute, University of California at Davis Medical Center, USA.
Chonchaiya
Weerasak
W
Rivera
Susan M
SM
Schneider
Andrea
A
Hagerman
Randi J
RJ
Faradz
Sultana M H
SM
Ethell
Iryna M
IM
Nguyen
Danh V
DV
D000293:Adolescent; D000900:Anti-Bacterial Agents / Q000009:adverse effects* / Q000627:therapeutic use; D002648:Child; D002653:Child Behavior Disorders / Q000175:diagnosis / Q000188:drug therapy; D002675:Child, Preschool; D005260:Female; D005500:Follow-Up Studies; D005600:Fragile X Syndrome / Q000175:diagnosis / Q000188:drug therapy*; D006801:Humans; D007223:Infant; D007805:Language Development Disorders / Q000175:diagnosis / Q000188:drug therapy; D008297:Male; D008911:Minocycline / Q000009:adverse effects* / Q000627:therapeutic use; D018696:Neuroprotective Agents / Q000009:adverse effects* / Q000627:therapeutic use; D016032:Randomized Controlled Trials as Topic; D055815:Young Adult
D000900:Anti-Bacterial Agents; D018696:Neuroprotective Agents; D008911:Minocycline